Egypt. J. Chem. Vol. 68 No.2, pp. **165 - 174** (2025)

Egyptian Journal of Chemistry

http://ejchem.journals.ekb.eg/

Secondary Hypertension: Diagnosis, Management, and Nursing Intervention-An Updated Review

Jamal Muaidh Alreshidi [1], Abdullah Nughaymish Alharbi [1], Abdulmajed Falah Aljohani [2], Fahad Khalifah Mordhy Alshammari [3], Ashawi Hamed Ashawi Alshammari [3], Alomrani,Mufleh Obaid [2], Adel Meter Alotaibi [4], Fares Saad Alharbi [4], Naif Ali Saeed Al Thabbahi [4], Nawaf Sahab Ghunim Alharbi [4], Yahya Qasim Khabarani[4], Abdulmajeed Hamad Albeladi[4],Muhammed Lafi Alosimi [4], Yousef Dhaif Allah Alzahrani [5], Hareth Mohmed Alharbi [4]

1Hail General Hospital, Ministry of Health, Saudi Arabia
2 Ministry of Health, Saudi Arabia
3 King Khalid Hospital, Ministry of Health, Saudi Arabia
4 Prince Sultan Military Medical City, Riyadh, Saudi Arabia
5 Prince Sultan Armed Forces Hospital, Taif, Saudi Arabia

Abstract

Background: Hypertension, a major risk factor for cardiovascular diseases, affects over 30% of adults worldwide. While essential hypertension accounts for most cases, secondary hypertension, caused by identifiable underlying conditions, is present in approximately 10% of individuals with hypertension. Recognizing secondary hypertension is crucial as it may lead to targeted therapies, potentially resolving hypertension. Key indicators for further investigation include resistant hypertension, sudden increases in BP, and hypertension in younger individuals without common risk factors. Various causes, such as renal parenchymal diseases, endocrine disorders, and drug-induced hypertension, contribute to the development of secondary hypertension.

Aim: This review aims to provide an updated overview of secondary hypertension, focusing on its diagnosis, management strategies, and nursing interventions.

Methods: A comprehensive review of recent studies on secondary hypertension was conducted, examining its etiology, pathophysiology, diagnostic approaches, and treatment strategies. Relevant clinical guidelines and research articles were analyzed to outline the nursing role in managing patients with secondary hypertension.

Results: Secondary hypertension's prevalence varies by age, with children under 12 and adults over 65 showing the highest rates. Renal parenchymal diseases and endocrine disorders, particularly primary aldosteronism, are the most common causes. The pathophysiology of secondary hypertension involves alterations in cardiac output and systemic vascular resistance due to factors like volume expansion, hormone imbalances, and vascular resistance. Diagnostic tests such as serum creatinine, renal ultrasound, and hormonal assays are critical in identifying underlying causes.

Conclusion: Early identification of secondary hypertension can lead to more effective management, potentially resolving hypertension through targeted treatment. Nurses play a vital role in early detection, patient education, and adherence to treatment plans, helping reduce complications associated with secondary hypertension.

Keywords: Secondary hypertension, diagnosis, management, renal parenchymal disease, endocrine disorders, nursing interventions, hypertension treatment.

.

1. Introduction

Hypertension represents a significant risk factor for cardiovascular diseases, with over 30% of the adult population currently affected in the modern era [1][2]. Although essential hypertension, characterized by the absence of an identifiable cause, accounts for most cases, approximately 10% of individuals with hypertension are diagnosed with secondary hypertension [3]. Secondary hypertension is defined as elevated blood pressure (BP) resulting from an identifiable underlying cause [4]. Given its relatively low prevalence, conducting routine evaluations in all hypertensive patients is neither cost-effective nor practical. Nevertheless, identifying the etiology and pathophysiology of secondary hypertension is crucial for selected patient populations. This process not only facilitates targeted therapeutic interventions but may also lead to the complete resolution of hypertension and discontinuation of antihypertensive medications. It is imperative for healthcare providers managing hypertension to recognize clinical indicators suggestive of a secondary etiology [5]. Indicators warranting further investigation for secondary hypertension include resistant hypertension, defined as persistent BP exceeding 140/90 mm Hg despite optimal

*Corresponding author e-mail: jmalreshidi@moh.gov.sa (Jamal Muaidh Alreshidi)
Receive Date: 26 December 2024, Revise Date: 18 January 2025, Accept Date: 19 January 2025
DOI: 10.21608/ejchem.2025.348047.11051

doses of at least three antihypertensive agents from different classes, including a diuretic [6]. Additionally, a sudden and unexplained increase in BP in patients with previously stable readings or the onset of hypertension before the age of 30 in non-Black individuals without other risk factors, such as obesity or family history, may indicate a secondary cause. Severe hypertension (BP greater than 180/110 mm Hg), end-organ damage—including acute kidney injury, hypertensive retinopathy, neurological complications, flash pulmonary edema, and left ventricular hypertrophy—and hypertension associated with electrolyte disturbances such as hypokalemia or metabolic alkalosis also require investigation. Moreover, the development of hypertension before puberty or the presence of abnormal patterns during 24-hour ambulatory BP monitoring, such as non-dipping or reverse dipping (where BP dips during the day rather than at night, contrary to normal circadian rhythms), are critical clinical signs suggestive of secondary hypertension [7].

Etiology

Numerous etiologies have been identified for secondary hypertension, which can be broadly categorized into various groups [8][9]. Renal parenchymal disease is recognized as the most prevalent cause of secondary hypertension. This condition encompasses a spectrum of renal disorders, including diabetic nephropathy, glomerulonephritis, interstitial renal parenchymal diseases, and polycystic kidney disease [10]. Hypertension is observed in more than half of the patients suffering from renal parenchymal diseases, with its prevalence increasing as the severity of the underlying renal condition progresses [11]. The development of hypertension in these patients exerts a detrimental impact on renal parenchymal disease, expediting the decline in renal function and ultimately leading to end-stage renal disease [12]. Hypertension associated with endocrine disorders arises from the excessive secretion of hormones. The most frequently implicated endocrine conditions include primary aldosteronism, pheochromocytoma, and Cushing's syndrome, with primary aldosteronism accounting for the majority of endocrine-related hypertension cases [13]. Other, less common endocrine causes include acromegaly, primary hyperparathyroidism, and various thyroid disorders, which are considered exceedingly rare contributors to secondary hypertension [14]. Hypertension resulting from renovascular disorders is an infrequent occurrence, attributed to the stenosis of unilateral or bilateral renal arteries [15]. In elderly populations, renal artery stenosis is predominantly caused by atherosclerosis, whereas in younger individuals, particularly females, fibromuscular hyperplasia is identified as the primary cause [16]. Coarctation of the aorta stands as a quintessential example of vascular disorders leading to secondary hypertension in young adults [17]. Additional, albeit rare, vascular causes include vasculitides affecting medium- or large-sized arteries and arteriovenous fistulas [18]. Obstructive sleep apnea, polycystic ovarian syndrome, preeclampsia, and certain drugs are recognized contributors to the etiology of secondary hypertension. Obstructive sleep apnea, in particular, has been associated with hypertension due to its detrimental effects on both the duration and quality of sleep, which are factors known to elevate blood pressure risk [19].

Drug-induced hypertension is a significant and often overlooked cause of secondary hypertension, necessitating a thorough review of the patient's medication history. A variety of drugs have been implicated in causing or exacerbating hypertension [20]. Among these, non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly associated with poor blood pressure control due to their widespread usage. Sodium-containing antacids are also implicated, along with medications prescribed for attention-deficit/hyperactivity disorder (ADHD), such as methylphenidate, amphetamine, dexmethylphenidate, and dextroamphetamine. Antidepressants, including monoamine oxidase inhibitors, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors, have also been linked to hypertension. Atypical antipsychotics like clozapine and olanzapine are additional culprits. Decongestants containing phenylephrine or pseudoephedrine, appetite suppressants, and herbal supplements such as St. John's wort, ephedra, and yohimbine may contribute to elevated blood pressure. Systemic corticosteroids, including dexamethasone, methylprednisolone, prednisone, prednisolone, and fludrocortisone, as well as mineralocorticoids like carbenoxolone, licorice, 9-alpha fludrocortisone, and ketoconazole, are frequently implicated. Hormonal therapies such as estrogens, androgens, and oral contraceptives can also lead to secondary hypertension. Immunosuppressants like cyclosporine, chronic recombinant human erythropoietin, and recreational drugs, including cocaine, methamphetamine, MDMA, and bath salts, are known to induce hypertension. Nicotine, alcohol, and certain chemotherapeutic agents, such as gemcitabine, which causes microvascular injury, are additional contributors to drug-induced hypertension.

Epidemiology

Secondary hypertension affects up to 10% of adults with hypertension, with its prevalence varying significantly across different age groups. It is most commonly observed at the age of extremes. Among children under 12 years, secondary hypertension accounts for approximately 70% to 85% of hypertension cases, whereas in adults aged 65 years and older, it constitutes about 17% of cases [21]. In contrast, adolescents between 12 and 18 years exhibit a prevalence of 10% to 15%, while individuals aged 19 to 39 years have the lowest prevalence of secondary hypertension [22]. Renal parenchymal diseases contribute to secondary hypertension in 3% to 5% of individuals diagnosed with hypertension. The prevalence increases with deteriorating renal function, with over two-thirds of patients experiencing advanced chronic kidney disease concurrently suffering from hypertension [23]. Primary aldosteronism represents the predominant endocrine cause of secondary hypertension, affecting up to 5% of hypertensive patients, and treatment of the underlying endocrine disorder often resolves the condition [24]. Renovascular hypertension, which affects approximately 1% of hypertensive individuals, exhibits a bimodal age distribution [25].

Pathophysiology

Arterial blood pressure is governed by cardiac output and systemic vascular resistance. Consequently, elevated cardiac output and increased systemic vascular resistance serve as the primary mechanisms underlying hypertension [26]. The various factors contributing to secondary hypertension alter these determinants of blood pressure. In renal parenchymal diseases, impaired renal function leads to intravascular volume expansion, with inappropriate activation of the renin-angiotensin-aldosterone system and the sympathetic nervous system further exacerbating hypertension [27]. Hypertension, in turn, worsens renal parenchymal disease and accelerates its progression to end-stage renal disease. In patients with advanced renal parenchymal disease, blood pressure largely depends on intravascular volume, emphasizing the importance of fluid balance in

managing hypertension in chronic kidney disease. Endocrine disorders induce hypertension through the actions of specific hormones. In primary aldosteronism, elevated aldosterone levels cause volume expansion through salt retention, while cortisol contributes similarly in Cushing's syndrome [28][29]. Pheochromocytoma-induced hypertension arises from heightened serum adrenaline and noradrenaline levels, which elevate cardiac output and systemic vascular resistance [30]. In vascular disorders, increased systemic vascular resistance is the primary mechanism, while secondary hyperaldosteronism plays a crucial role in hypertension associated with renal artery stenosis [31].



Figure 1: Secondary Hypertension.

History and Physical Examination

A comprehensive medical history and detailed physical examination are essential for identifying the underlying cause of secondary hypertension. Key features indicative of secondary hypertension include the onset of hypertension at extreme ages, accelerated end-organ dysfunction, resistant hypertension, and abrupt elevations in blood pressure in individuals previously stable on antihypertensive therapy [32][33][34]. Certain historical and clinical findings suggest specific etiologies. Snoring, obesity, and daytime sleepiness may indicate obstructive sleep apnea [35]. A history of renal insufficiency, atherosclerotic cardiovascular disease, or edema could necessitate an evaluation for chronic kidney disease [36]. Recurrent urinary tract infections, kidney stones, abdominal or flank pain, hematuria, and progressive renal failure may point to autosomal dominant polycystic kidney disease [37]. Worsening renal function following angiotensin-converting enzyme inhibitors (ACEi) therapy or the presence of systolic/diastolic abdominal bruits suggests renovascular disease [38]. Pheochromocytoma or paragangliomas may manifest with episodic hypertension, headaches, and palpitations during acute stress or perioperative settings [39]. Delayed femoral pulses, radiofemoral delay, and inter-arm blood pressure discrepancies are observed in coarctation of the aorta and vasculitis conditions [40]. Cushing syndrome/disease presents with weight gain, fatigue, moon facies, dorsal hump, purple striae, truncal obesity, and hirsutism [41]. Hypothyroidism may manifest as fatigue, weight loss, diastolic hypertension, and muscle weakness, while hyperthyroidism can be presented with heat intolerance, weight loss, palpitations, systolic hypertension, exophthalmos, and tremors. Hyperparathyroidism may cause kidney stones, osteoporosis, depression, lethargy, and muscle weakness [42]. Acromegaly presents with headaches, visual disturbances, and enlargement of the hands, feet, and tongue. Features such as heartburn, Raynaud's phenomenon, and nail pitting suggest scleroderma.

Evaluation:

Evaluation of secondary hypertension begins with investigations tailored to the patient's history and clinical findings. Confirmatory diagnostic procedures are individualized and typically follow initial screening tests. Current guidelines advocate screening for secondary hypertension in patients exhibiting new-onset or resistant hypertension, particularly those displaying symptoms or signs indicative of secondary causes. A positive screening test warrants confirmatory testing, and referral to specialized clinicians is often advisable [43].

Renal Parenchymal Disease: The initial diagnostic workup for renal parenchymal disease includes serum creatinine measurement with an estimated glomerular filtration rate (eGFR), a detailed urinalysis, and protein quantification using a protein-to-creatinine ratio. Renal ultrasound serves as an important non-invasive imaging tool. For definitive diagnosis and understanding of specific renal pathologies, renal biopsy followed by histopathological examination is considered the gold

standard [44][45][46]. Patients with abnormal screening results should be referred to a nephrologist for comprehensive evaluation and management of renal dysfunction.

Endocrine Disorders: Hypertension accompanied by hypokalemia often suggests primary aldosteronism, particularly in individuals with a family history of hypertension or early cerebrovascular events. Screening for primary aldosteronism involves calculating the plasma aldosterone-to-renin ratio. This test should be performed at least four weeks after discontinuing aldosterone antagonists and correcting hypokalemia [47]. Confirmatory diagnostic tests include 24-hour urinary aldosterone measurement post-sodium loading and plasma aldosterone levels after intravenous saline infusion. Adrenal imaging aids in localizing the lesion, and renal vein sampling may be used selectively [48]. Screening for pheochromocytoma or paraganglioma is indicated in patients experiencing episodic hypertension, palpitations, headaches, postural hypotension, or signs of neurofibromatosis. The measurement of plasma or urinary metanephrines is the preferred initial test, while imaging via computed tomography (CT) or magnetic resonance imaging (MRI) localizes the tumor [39]. For suspected Cushing syndrome, the overnight dexamethasone suppression test serves as the primary screening tool, with confirmatory tests including 24-hour urinary free cortisol and midnight salivary cortisol. Imaging is used for lesion localization [49]. Thyroid disorders, though rare causes of secondary hypertension, can be diagnosed by measuring thyroid-stimulating hormone (TSH) and free T4/T3 levels. Ultrasound and biopsy may be warranted in patients with suspected thyroid malignancies. Screening for hyperparathyroidism involves serum calcium measurement, with serum parathyroid hormone levels used for diagnosis.

Reno-Vascular Hypertension: Suspected renal artery stenosis is commonly associated with uncontrolled hypertension, renal bruit, or renal function decline following the administration of angiotensin-converting enzyme (ACE) inhibitors. Initial screening involves ultrasound renal Doppler imaging. For patients with a high index of suspicion or inconclusive Doppler results, computed tomographic angiography (CTA) or magnetic resonance angiography (MRA) may be utilized [51]. The use of bilateral, selective renal artery angiography is now rare, owing to advancements in non-invasive imaging techniques.

Vascular and Other Causes of Hypertension: Coarctation of the aorta is a principal cause of secondary hypertension in this category, with echocardiography serving as the optimal screening and diagnostic modality for detecting this condition. Computed tomographic aortography (CTA) and magnetic resonance angiography (MRA) are recommended for further diagnosis and confirmation of coarctation of the aorta, as well as for the detection of vasculitis [52]. Polysomnography, particularly in-laboratory polysomnography, is considered the gold standard for diagnosing obstructive sleep apnea when there is clinical suspicion. Findings consistent with scleroderma, such as thrombotic microangiopathy, autoantibodies against RNA polymerase III, and positive antinuclear antibodies (ANA), may assist in diagnosis [53].

Treatment / Management

The management of secondary hypertension involves achieving adequate blood pressure control through both a healthy lifestyle and appropriate antihypertensive medications, while addressing the underlying causes of hypertension. Referral to specialists with expertise in treating these secondary causes is recommended [43]. Identifying medications that may provoke or exacerbate hypertension is a crucial aspect of management in patients with secondary hypertension. This section outlines the treatment approaches for more common causes of secondary hypertension.

Renal Parenchymal Disease

Diabetic nephropathy, chronic glomerulonephritis, glomerulosclerosis, and autosomal dominant polycystic kidney disease (ADPKD) are the most prevalent renal parenchymal diseases contributing to secondary hypertension, all of which lead to chronic kidney disease (CKD) [54]. Hypertension is present in over two-thirds of patients with CKD and significantly accelerates its progression to end-stage renal disease [23]. Therefore, maintaining optimal blood pressure control is essential in this patient population. Currently, there is no cure for CKD, and treatment primarily focuses on addressing reversible causes that contribute to the progression of kidney disease to more advanced stages [55]. Effective blood pressure management is a cornerstone of CKD care, with renin-angiotensin (RA) antagonists recommended as the preferred pharmacological approach to treating hypertension in CKD. These RA-blocking medications not only control blood pressure but also help prevent CKD progression, particularly in patients with proteinuria [56][57].

Renovascular Hypertension

The management of renovascular hypertension, specifically renal artery stenosis, involves both medical therapy and revascularization. Medical therapy includes antihypertensive medications, antiplatelets, statins, dietary modifications, and lifestyle changes, particularly for patients with atherosclerotic disease [58]. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are the drugs of choice for managing hypertension in patients with unilateral renal artery stenosis, although they are contraindicated in bilateral renal artery stenosis due to the risk of acute renal dysfunction [59]. Other pharmacologic treatments include calcium channel blockers and thiazide diuretics. In select patients, particularly those with fibromuscular dysplasia, percutaneous revascularization is recommended alongside medical therapy. The combination of pharmacological treatment and percutaneous revascularization has been shown to significantly reduce blood pressure and provides long-term renoprotective effects for these patients [38]. Revascularization may be more beneficial than medical therapy alone in certain cases, such as patients with recurrent flash pulmonary edema, those who have not responded to or cannot tolerate optimal medical treatment, individuals with refractory hypertension, and those experiencing unexplained or progressive renal function decline. Revascularization is also considered for patients who recently began dialysis with suspected renal artery stenosis or experienced a significant increase in serum creatinine after medical therapy, especially if the renal resistive index is less than 80 mmHg on Doppler ultrasound.

Endocrine Hypertension

Unilateral primary aldosteronism, such as that caused by unilateral adrenal hyperplasia or aldosterone-producing adenomas, is treated with unilateral laparoscopic adrenalectomy. For patients who are not candidates for surgery or those with bilateral adrenal disease, medical management with a mineralocorticoid receptor antagonist is recommended, with

spironolactone being the drug of choice for primary aldosteronism [47]. In cases of Cushing Syndrome or Cushing Disease, surgical resection of the tumor or lesion, whether performed through an open or laparoscopic approach, remains the preferred treatment. Surgical resection is also the definitive treatment for pheochromocytoma, although preoperative management with alpha and beta-adrenergic blocking agents is critical. Alpha-adrenergic blockers should be initiated first, followed by the addition of beta-blockers to manage tachyarrhythmias. It is essential that beta-blockers are not used before alpha-adrenergic blockade, as doing so can precipitate a hypertensive crisis due to unopposed alpha-adrenergic effects. In cases of pheochromocytoma crisis, intravenous phentolamine is administered, followed by the introduction of oral alpha-adrenergic blockers [60][61]. Thyroid disorders associated with hypertension are treated with thyroid replacement therapy for hypothyroidism and antithyroid drugs for hyperthyroidism. Treatment for other thyroid conditions is guided by their underlying pathophysiology. For hypertension related to acromegaly, the definitive treatment is transsphenoidal resection of the hormone-producing tumor [62].

Vascular Hypertension

Coarctation of the aorta is a leading cause of vascular hypertension in younger patients. The choice of antihypertensive medications for this group is influenced by concomitant conditions, although the definitive treatment is percutaneous or surgical correction of the coarctation. Early correction of coarctation generally results in better long-term outcomes, though approximately one-third of patients remain hypertensive even after surgical intervention [63]. Vasculitides affecting large vessels, such as Takayasu Arteritis, can also lead to hypertension due to increased systemic vascular resistance. Treatment of secondary hypertension resulting from vasculitis includes the use of corticosteroids or other immunosuppressive agents in combination with antihypertensive medications [64].

Obstructive Sleep Apnea

The cornerstone of treatment for obstructive sleep apnea (OSA) is continuous positive airway pressure (CPAP) therapy. However, a combination of CPAP and lifestyle modifications, such as weight loss, has a synergistic effect in reducing blood pressure, outperforming either intervention alone [65]. For patients with mild to moderate OSA, oral appliances are a viable alternative to CPAP, showing non-inferior results in blood pressure reduction and potentially better patient compliance [66]. In cases where these treatments are insufficient, certain upper airway surgeries, such as uvulopalatopharyngoplasty (UPPP) for adults and tonsillectomy and adenoidectomy for children, may be considered to alleviate symptoms and help reduce blood pressure [67].

Pregnancy-Related Hypertension

Management strategies for hypertension during pregnancy primarily involve lifestyle modifications and the use of antihypertensive medications. The most commonly employed antihypertensive agents during pregnancy include labetalol, nifedipine, and methyldopa. In situations where a rapid reduction in blood pressure is necessary, intravenous labetalol or hydralazine can be considered [68]. In cases of severe hypertension such as severe preeclampsia, eclampsia, and HELLP syndrome, delivery is typically the recommended course of action, particularly when the pregnancy reaches 37 weeks of gestation [69].

Differential Diagnosis

The differential diagnosis of secondary hypertension encompasses various conditions, including chronic kidney disease, autosomal dominant polycystic kidney disease, renal artery stenosis, fibromuscular dysplasia, primary aldosteronism, Cushing syndrome/disease, hyperthyroidism, hypothyroidism, hyperparathyroidism, pheochromocytoma, acromegaly, congenital adrenal hyperplasia, coarctation of the aorta, obstructive sleep apnea, drug-induced hypertension, pregnancy, and scleroderma. A thorough history and clinical examination are essential for effective screening and early detection of the underlying cause of secondary hypertension [3].

Prognosis

Secondary hypertension tends to be more resistant to antihypertensive treatment when the underlying cause remains unidentified or untreated. This may lead to early onset of end-organ dysfunction, hypertensive crises, and cardiovascular events, often at a younger age [70]. However, with prompt identification and appropriate treatment of the underlying cause, the prognosis for secondary hypertension can be favorable [71].

Complications

Hypertension is the most prevalent non-communicable disease globally and a significant risk factor for various cardiovascular conditions, including coronary artery disease, cerebrovascular accidents, and peripheral arterial diseases [72][73]. The microvascular complications of hypertension encompass chronic kidney disease and hypertensive retinopathy [74]. Additionally, hypertension heightens the risk of atrial fibrillation and heart failure, particularly in the elderly population [75]. While secondary hypertension shares many complications with essential hypertension, certain complications are more frequently observed in secondary hypertension. Patients with secondary hypertension commonly present with resistant hypertension, characterized by uncontrolled blood pressure despite maximally tolerated doses of at least three antihypertensive medications, including a diuretic [70]. If not diagnosed and treated in a timely manner, secondary hypertension can exacerbate end-organ damage and markedly increase the risk of premature cardiovascular events [4].

Consultations

The management of secondary hypertension requires a multidisciplinary approach. Patients diagnosed with secondary hypertension should be referred to clinicians with specialized expertise to appropriately address the underlying causes of the condition. Consultations with the following specialties are recommended for optimal management:

- Internal medicine
- Nephrology
- Cardiology
- Endocrinology
- Neurology
- Cardiac/Vascular surgery

- Rheumatology

Patient Education

Secondary hypertension is a potentially life-threatening condition that accelerates cardiovascular complications and end-organ damage. It is crucial for patients to recognize symptoms indicative of secondary causes of hypertension and seek early consultation with their primary care physician to facilitate timely diagnosis and management. Individuals undergoing hypertension treatment should adhere to a healthy lifestyle, comply with prescribed medications, and regularly monitor their blood pressure at home. Patients should promptly inform their physician of any new symptoms or changes in blood pressure, as these may necessitate evaluation for a secondary cause of hypertension.

Other Issues

Secondary hypertension accounts for approximately 10% of all hypertension cases and is more prevalent in younger individuals. It should be suspected in individuals presenting with: Signs and symptoms indicative of a secondary cause of hypertension. Hypertension diagnosed at the extremes of age, Accelerated end-organ dysfunction, Resistant hypertension, and A sudden increase in blood pressure in individuals with previously well-controlled hypertension.

Enhancing Healthcare Team Outcomes

Secondary hypertension is frequently diagnosed incidentally or in patients presenting with resistant hypertension and associated end-organ dysfunction. The diagnosis and management of secondary hypertension require a collaborative, multidisciplinary approach. Effective inter-professional communication is crucial in identifying the etiology of secondary hypertension and ensuring proper treatment. A comprehensive healthcare team—including a hypertension nurse, primary care physician, cardiologist, nephrologist, neurologist, endocrinologist, cardiovascular surgeon, and rheumatologist—plays a pivotal role in the management of secondary hypertension. This collaborative effort is essential for improving long-term patient outcomes and minimizing the economic burden on the healthcare system [76].

Nursing Intervention Protocols in the Management of Secondary Hypertension:

Secondary hypertension, unlike primary hypertension, arises from an underlying medical condition, such as chronic kidney disease, endocrine disorders, or vascular anomalies. Managing secondary hypertension requires a comprehensive, multidisciplinary approach, in which nursing interventions play a pivotal role. Nurses, as frontline healthcare providers, are integral to monitoring, educating, and supporting patients, ensuring timely interventions, and facilitating optimal management. The following protocols outline key nursing interventions for patients diagnosed with secondary hypertension, emphasizing early detection, patient education, pharmacological support, and lifestyle modification.

Monitoring and Assessment

The first step in managing secondary hypertension is thorough and consistent monitoring. Nurses should conduct comprehensive assessments, which include regular blood pressure measurements, to ensure that the patient's hypertension is being controlled effectively. Blood pressure should be measured using appropriate techniques—using a calibrated sphygmomanometer with the patient seated, relaxed, and at rest for at least five minutes. Accurate documentation of blood pressure readings, including systolic and diastolic values, is essential for tracking progress or identifying changes in the patient's condition. Nurses must also assess for signs and symptoms of hypertensive crisis, which could indicate inadequate control of blood pressure or exacerbation of the underlying cause. Symptoms such as severe headache, chest pain, visual disturbances, or shortness of breath should be addressed immediately, as they may indicate end-organ damage or an imminent hypertensive emergency. In addition to blood pressure, nurses should assess other vital signs, including heart rate, respiratory rate, and temperature, which can provide insight into the patient's overall health status and response to treatment. The assessment should also include monitoring laboratory values relevant to secondary hypertension, such as kidney function tests, thyroid function tests, and electrolyte levels, as they may indicate the presence of an underlying disorder like hyperthyroidism or chronic kidney disease. Regular weight monitoring is also critical, as sudden weight gain or loss can be indicative of worsening kidney function or fluid retention, which can exacerbate hypertension.

Pharmacological Support and Administration

Pharmacological management forms the cornerstone of hypertension treatment. Nurses are responsible for administering antihypertensive medications in accordance with prescribed treatment regimens and ensuring that patients understand their medication schedules. The most commonly used antihypertensive agents in secondary hypertension include beta-blockers (e.g., labetalol), calcium channel blockers (e.g., nifedipine), and centrally acting agents (e.g., methyldopa), among others. It is vital for nurses to monitor the patient's response to medications, observing adverse effects such as hypotension, dizziness, or bradycardia, and reporting any concerns to the healthcare provider. Nurses should also be familiar with the potential drug interactions that may occur when antihypertensive agents are used in conjunction with medications to treat the underlying condition (e.g., corticosteroids in Cushing's syndrome or anti-thyroid drugs in hyperthyroidism). In cases of severe hypertension or hypertensive emergencies, intravenous (IV) antihypertensive medications, such as labetalol or hydralazine, may be required for rapid blood pressure reduction. Nurses must follow hospital protocols for the administration of these IV medications, ensuring correct dosages and titration based on continuous blood pressure monitoring. Nurses should also be vigilant for any adverse reactions, including hypotension, arrhythmias, or electrolyte imbalances, and promptly address any concerns with the healthcare team.

Patient Education and Counseling

Patient education is a cornerstone of effective hypertension management. Nurses must empower patients with the knowledge needed to understand their condition, the importance of adhering to prescribed therapies, and the lifestyle modifications required for optimal control. Educating patients about secondary hypertension involves explaining the relationship between the underlying medical condition and hypertension. For example, a patient with hyperthyroidism should be educated on how thyroid hormone imbalances can contribute to elevated blood pressure, and a patient with chronic kidney disease should understand how renal function affects blood pressure regulation. Nurses should provide clear instructions on how to take medications correctly, including the timing, dosage, and possible side effects. Emphasizing the importance of

medication adherence is essential, as non-compliance can result in inadequate blood pressure control and the progression of organ damage. Nurses should also instruct patients to regularly monitor their blood pressure at home, providing guidance on how to use blood pressure monitors and when to seek medical attention if readings are consistently high or show sudden fluctuations. In addition to medication, lifestyle modification is critical in the management of secondary hypertension. Nurses should educate patients about the importance of a healthy diet, weight management, physical activity, and stress reduction. For example, a low-sodium, high-potassium diet can help regulate blood pressure, while regular exercise can improve cardiovascular health. Nurses should encourage patients to reduce alcohol consumption, quit smoking, and manage stress through relaxation techniques such as deep breathing or meditation. Educating patients about the impact of these lifestyle changes on both their blood pressure and overall health can significantly improve outcomes.

Managing Complications and Crisis Situations

Hypertensive crises, both hypertensive urgencies and emergencies, are a potential complication in secondary hypertension, especially in patients who have not received timely or appropriate treatment. Nurses must be prepared to respond swiftly to these crises. A hypertensive urgency may be present with severe headache, shortness of breath, or anxiety, while a hypertensive emergency could involve symptoms such as chest pain, confusion, or organ dysfunction. In both cases, nurses should implement rapid blood pressure lowering strategies under the direction of the healthcare provider, which may involve IV antihypertensive medications, oxygen administration, and continuous monitoring of vital signs. Nurses should also be vigilant for signs of end-organ damage, including signs of stroke, heart failure, or kidney failure. In patients with chronic kidney disease, for example, nurses should monitor symptoms of fluid retention, such as edema, weight gain, or shortness of breath, and collaborate with the healthcare team to adjust fluid management and medications accordingly.

5. Multidisciplinary Collaboration

Nurses are essential members of the healthcare team and play a critical role in facilitating communication and coordination among various specialists, such as nephrologists, endocrinologists, cardiologists, and other healthcare providers. Nurses should provide timely updates on the patient's condition, monitor laboratory results, and ensure that any changes in the patient's status are communicated effectively to the rest of the team. Regular case discussions with specialists help ensure a holistic approach to treatment, ensuring that both the secondary hypertension and its underlying causes are addressed simultaneously. Nursing interventions in the management of secondary hypertension are multifaceted, involving continuous monitoring, pharmacological support, patient education, and timely response to complications. Nurses are integral in ensuring optimal management by advocating for patients, providing education, and facilitating collaboration among healthcare providers. With the implementation of these protocols, patients with secondary hypertension can achieve better blood pressure control, prevent end-organ damage, and improve overall health outcomes. Effective nursing interventions are vital in reducing the burden of secondary hypertension on both the individual and the healthcare system.

Conclusion:

Secondary hypertension, though less prevalent than essential hypertension, poses a significant challenge to clinicians due to its multifactorial nature. It often requires a high index of suspicion, as the underlying causes can vary widely, including renal parenchymal diseases, endocrine disorders, renovascular hypertension, and drug-induced hypertension. The recognition of secondary hypertension is essential for preventing complications, as addressing the root cause can not only resolve hypertension but also improve the patient's overall health. Renal parenchymal disease is the most common cause, often exacerbating hypertension and leading to further renal decline. Endocrine causes, particularly primary aldosteronism, contribute significantly to the condition, with the treatment of these disorders often resolving hypertension. Drug-induced hypertension is another frequently overlooked cause, making it crucial for clinicians to conduct a thorough review of patients' medication histories. Obstructive sleep apnea and vascular conditions like coarctation of the aorta also contribute to secondary hypertension, necessitating specialized interventions. Diagnosis involves a detailed clinical evaluation, including a comprehensive medical history, physical examination, and targeted diagnostic tests such as serum creatinine, renal ultrasound, and hormonal assays. Imaging techniques like CT or MRI are essential in confirming specific conditions like pheochromocytomas or renovascular diseases. The treatment of secondary hypertension depends on its underlying cause, with interventions ranging from pharmacological management to surgical procedures. For nursing professionals, understanding the diverse etiology of secondary hypertension and being aware of its clinical signs is crucial in early detection. Nurses play a pivotal role in educating patients, monitoring blood pressure, managing medications, and ensuring patient adherence to prescribed therapies. Moreover, nurses assist in the identification of red flags, such as sudden BP increases or resistance to treatment, which may prompt further investigation into secondary causes. In conclusion, secondary hypertension requires a multifaceted approach to diagnosis and management. Early recognition, appropriate diagnostic workup, and effective intervention can prevent the long-term complications associated with this condition. Nurses are integral in managing patients with secondary hypertension, offering essential support in both the clinical setting and the community. Their involvement is key to improving outcomes and ensuring that patients receive the most appropriate and timely care.

References:

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet (London, England). 2021 Sep 11:398(10304):957-980. doi: 10.1016/S0140-6736(21)01330-1.
2. Chow CK, Gupta R. Blood pressure control: a challenge to global health systems. Lancet (London, England). 2019 Aug 24:394(10199):613-615. doi: 10.1016/S0140-6736(19)31293-0.
3. Rossi GP, Bisogni V, Rossitto G, Maiolino G, Cesari M, Zhu R, Seccia TM. Practice Recommendations for Diagnosis and Treatment of the Most Common Forms of Secondary Hypertension. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2020 Dec:27(6):547-560. doi: 10.1007/s40292-020-00415-9.
4. Rimoldi SF,Scherrer U,Messerli FH, Secondary arterial hypertension: when, who, and how to screen? European heart journal. 2014 May 14

5. Ott C,Schneider MP,Schmieder RE, Ruling out secondary causes of hypertension. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 2013 May
6. Lamirault G, Artifoni M, Daniel M, Barber-Chamoux N, Nantes University Hospital Working Group On Hypertension. Resistant Hypertension: Novel Insights. Current hypertension reviews. 2020:16(1):61-72. doi: 10.2174/1573402115666191011111402.
7. Cuspidi C, Sala C, Tadic M, Gherbesi E, De Giorgi A, Grassi G, Mancia G. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: An updated review. Journal of clinical hypertension (Greenwich, Conn.). 2017 Jul:19(7):713-721. doi: 10.1111/jch.13023. Epub
8. Taler SJ. Secondary causes of hypertension. Primary care. 2008 Sep:35(3):489-500, vi. doi: 10.1016/j.pop.2008.06.001.
9. Chiong JR,Aronow WS,Khan IA,Nair CK,Vijayaraghavan K,Dart RA,Behrenbeck TR,Geraci SA, Secondary hypertension: current diagnosis and treatment. International journal of cardiology. 2008 Feb 20
10. Whaley-Connell AT, Sowers JR, Stevens LA, McFarlane SI, Shlipak MG, Norris KC, Chen SC, Qiu Y, Wang C, Li S, Vassalotti JA, Collins AJ, Kidney Early Evaluation Program Investigators. CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2008 Apr:51(4 Suppl 2):S13-20. doi: 10.1053/j.ajkd.2007.12.016.
11. Rao MV, Qiu Y, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2008 Apr:51(4 Suppl 2):S30-7. doi: 10.1053/j.ajkd.2007.12.012.
12. Hamrahian SM, Falkner B. Hypertension in Chronic Kidney Disease. Advances in experimental medicine and biology. 2017:956():307-325. doi: 10.1007/5584_2016_84.
13. Sica DA, Endocrine causes of secondary hypertension. Journal of clinical hypertension (Greenwich, Conn.). 2008 Jul
14. de Silva T, Cosentino G, Ganji S, Riera-Gonzalez A, Hsia DS. Endocrine Causes of Hypertension. Current hypertension reports. 2020 Oct 20:22(11):97. doi: 10.1007/s11906-020-01108-3.
15. Mannemuddhu SS, Ojeda JC, Yadav A. Renovascular Hypertension. Primary care. 2020 Dec:47(4):631-644. doi: 10.1016/j.pop.2020.08.009.
16. Ram CV,Clagett GP,Radford LR, Renovascular hypertension. Seminars in nephrology. 1995 Mar
17. Kim YY, Andrade L, Cook SC. Aortic Coarctation. Cardiology clinics. 2020 Aug:38(3):337-351. doi: 10.1016/j.ccl.2020.04.003.
18. Haller H,Limbourg F,Schmidt BM,Menne J, [Rare forms of hypertension : From pheochromocytoma to vasculitis]. Der Internist. 2015 Mar
19. Kapa S, Sert Kuniyoshi FH, Somers VK. Sleep apnea and hypertension: interactions and implications for management. Hypertension (Dallas, Tex. : 1979). 2008 Mar:51(3):605-8. doi: 10.1161/HYPERTENSIONAHA.106.076190.
20. Masi S, Uliana M, Gesi M, Taddei S, Virdis A. Drug-induced hypertension: Know the problem to know how to deal with it. Vascular pharmacology. 2019 Apr:115():84-88. doi: 10.1016/j.vph.2019.02.002.
21. Viera AJ,Neutze DM, Diagnosis of secondary hypertension: an age-based approach. American family physician. 2010 Dec 15;
22. Chrysaidou K, Chainoglou A, Karava V, Dotis J, Printza N, Stabouli S. Secondary Hypertension in Children and Adolescents: Novel Insights. Current hypertension reviews. 2020:16(1):37-44. doi: 10.2174/1573402115666190416152820.
23. Kimura G, Glomerular function reserve and sodium sensitivity. Clinical and experimental nephrology. 2005 Jun
24. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. Journal of the American College of Cardiology. 2006 Dec 5:48(11):2293-300
25. Matuszkiewicz-Rowińska J, Wieliczko M. [Renovascular hypertension]. Wiadomosci lekarskie (Warsaw, Poland : 1960). 2015:68(4 Pt 2):623-5
26. Guyton AC, The relationship of cardiac output and arterial pressure control. Circulation. 1981 Dec
27. Konishi Y, Imanishi M, Okamura M, Yoshioka K, Okumura M, Okada N, Tanaka S, Fujii S, Kimura G. Relationship of renal histological damage to glomerular hypertension in patients with immunoglobulin A nephropathy. Journal of hypertension. 2000 Jan:18(1):103-9
28. Silhol F,Sarlon-Bartoli G,Vaïsse B, [Hormonal Assessment of Secondary Hypertension - How to do it and what to expect?]. Presse medicale (Paris, France : 1983). 2019 Dec
29. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical endocrinology. 2004 Dec:61(6):768-77
30. Farrugia FA, Charalampopoulos A. Pheochromocytoma. Endocrine regulations. 2019 Jul 1:53(3):191-212. doi: 10.2478/enr-2019-0020.
31. Herrmann SM, Textor SC. Renovascular Hypertension. Endocrinology and metabolism clinics of North America. 2019 Dec:48(4):765-778. doi: 10.1016/j.ecl.2019.08.007.
32. Vongpatanasin W, Resistant hypertension: a review of diagnosis and management. JAMA. 2014 Jun 4
33. Doyle AE. Hypertension and vascular disease. American journal of hypertension. 1991 Feb:4(2 Pt 2):103S-106S
34. Chazova IE, Aksenova AV, Oschepkova EV. Clinical features of arterial hypertension in men and women (according to the National Registry of Arterial Hypertension). Terapevticheskii arkhiv. 2019 Mar 2:91(1):8-16. doi: 10.26442/00403660.2019.01.000021.

35. Silverberg DS, Oksenberg A. Essential and secondary hypertension and sleep-disordered breathing: a unifying hypothesis. Journal of human hypertension. 1996 Jun:10(6):353-63
36. Preston RA, Singer I, Epstein M. Renal Parenchymal Hypertension: current concepts of pathogenesis and management. Archives of internal medicine. 1996 Mar 25:156(6):602-11
37. Higashihara E, Aso Y, Shimazaki J, Ito H, Koiso K, Sakai O. Clinical aspects of polycystic kidney disease. The Journal of urology. 1992 Feb:147(2):329-32
38. Tafur JD, White CJ. Renal Artery Stenosis: When to Revascularize in 2017. Current problems in cardiology. 2017 Apr:42(4):110-135. doi: 10.1016/j.cpcardiol.2017.01.004.
39. Farrugia FA,Martikos G,Tzanetis P,Charalampopoulos A,Misiakos E,Zavras N,Sotiropoulos D, Pheochromocytoma, diagnosis and treatment: Review of the literature. Endocrine regulations. 2017 Jul 1
40. Alsallami AYA, Amber K. Blood Pressure Behavior After Correction Adult Coarctation of Aorta Short Term Follows Up. Medical archives (Sarajevo, Bosnia and Herzegovina). 2021 Aug:75(4):269-273. doi: 10.5455/medarh.2021.75.269-273.
41. Nieman LK. Diagnosis of Cushing's Syndrome in the Modern Era. Endocrinology and metabolism clinics of North America. 2018 Jun:47(2):259-273. doi: 10.1016/j.ecl.2018.02.001.
42. Kowalski GJ, Buła G, Żądło D, Gawrychowska A, Gawrychowski J. Primary hyperparathyroidism. Endokrynologia Polska. 2020:71(3):260-270. doi: 10.5603/EP.a2020.0028.
43. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018 May 15:71(19):e127-e248. doi: 10.1016/j.jacc.2017.11.006.
44. Drawz P,Rahman M, Chronic kidney disease. Annals of internal medicine. 2015 Jun 2
45. Bandari J, Fuller TW, Turner Ii RM, D'Agostino LA. Renal biopsy for medical renal disease: indications and contraindications. The Canadian journal of urology. 2016 Feb:23(1):8121-6
46. Bermejo S, Pascual J, Soler MJ. The current role of renal biopsy in diabetic patients. Minerva medica. 2018 Apr:109(2):116-125. doi: 10.23736/S0026-4806.17.05446-5.
47. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. The lancet. Diabetes & endocrinology. 2021 Dec:9(12):876-892. doi: 10.1016/S2213-8587(21)00210-2.
48. Lee FT, Elaraj D. Evaluation and Management of Primary Hyperaldosteronism. The Surgical clinics of North America. 2019 Aug:99(4):731-745. doi: 10.1016/j.suc.2019.04.010.
49. Ceccato F, Boscaro M. Cushing's Syndrome: Screening and Diagnosis. High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension. 2016 Sep:23(3):209-15. doi: 10.1007/s40292-016-0153-4.
50. Alarcon G, Figueredo V, Tarkoff J. Thyroid Disorders. Pediatrics in review. 2021 Nov:42(11):604-618. doi: 10.1542/pir.2020-001420.
51. Safian RD. Renal artery stenosis. Progress in cardiovascular diseases. 2021 Mar-Apr:65():60-70. doi: 10.1016/j.pcad.2021.03.003.
52. Keser G,Aksu K, Diagnosis and differential diagnosis of large-vessel vasculitides. Rheumatology international.
53. Rongioletti F, Ferreli C, Atzori L, Bottoni U, Soda G. Scleroderma with an update about clinico-pathological correlation. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. 2018 Apr:153(2):208-215. doi: 10.23736/S0392-0488.18.05922-9.
54. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet (London, England). 2017 Mar 25:389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5.
55. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney international. 2020 Oct:98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019.
56. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney international. 2021 Mar:99(3S):S1-S87. doi: 10.1016/j.kint.2020.11.003.
57. Pugh D, Gallacher PJ, Dhaun N. Management of Hypertension in Chronic Kidney Disease. Drugs. 2019 Mar:79(4):365-379. doi: 10.1007/s40265-019-1064-1.
58. Colbert GB, Abra G, Lerma EV. Update and review of renal artery stenosis. Disease-a-month : DM. 2021 Jun:67(6):101118. doi: 10.1016/j.disamonth.2020.101118.
59. Murdoch DR. Taking precautions with angiotensin converting enzyme inhibitors. Screening for unilateral renal artery stenosis cannot be justified. BMJ (Clinical research ed.). 1999 Jan 23:318(7178):257-8
60. Naranjo J, Dodd S, Martin YN. Perioperative Management of Pheochromocytoma. Journal of cardiothoracic and vascular anesthesia. 2017 Aug:31(4):1427-1439. doi: 10.1053/j.jvca.2017.02.023.
61. Bartikoski SR, Reschke DJ. Pheochromocytoma Crisis in the Emergency Department. Cureus. 2021 Mar 3:13(3):e13683. doi: 10.7759/cureus.13683.
62. Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S. Multidisciplinary management of acromegaly: A consensus. Reviews in endocrine & metabolic disorders. 2020 Dec:21(4):667-678. doi: 10.1007/s11154-020-09588-z.

63. Toro-Salazar OH,Steinberger J,Thomas W,Rocchini AP,Carpenter B,Moller JH, Long-term follow-up of patients after coarctation of the aorta repair. The American journal of cardiology.
64. Keser G, Aksu K, Direskeneli H. Takayasu arteritis: an update. Turkish journal of medical sciences. 2018 Aug 16:48(4):681-697. doi: 10.3906/sag-1804-136.
65. Salman LA, Shulman R, Cohen JB. Obstructive Sleep Apnea, Hypertension, and Cardiovascular Risk: Epidemiology, Pathophysiology, and Management. Current cardiology reports. 2020 Jan 18:22(2):6. doi: 10.1007/s11886-020-1257-y.
66. Dieltjens M, Vanderveken O. Oral Appliances in Obstructive Sleep Apnea. Healthcare (Basel, Switzerland). 2019 Nov 8:7(4):. doi: 10.3390/healthcare7040141.
67. Carvalho B,Hsia J,Capasso R, Surgical therapy of obstructive sleep apnea: a review. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2012
68. Magee LA, von Dadelszen P. State-of-the-Art Diagnosis and Treatment of Hypertension in Pregnancy. Mayo Clinic proceedings. 2018 Nov:93(11):1664-1677. doi: 10.1016/j.mayocp.2018.04.033.
69. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet (London, England). 2021 Jul 24:398(10297):341-354. doi: 10.1016/S0140-6736(20)32335-7.
70. Doroszko A, Janus A, Szahidewicz-Krupska E, Mazur G, Derkacz A. Resistant Hypertension. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2016 Jan-Feb:25(1):173-83. doi: 10.17219/acem/58998.
71. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065.
72. Paudel P, Chalise S, Neupane DR, Adhikari N, Paudel S, Dangi NB. Prevalence of Hypertension in a Community. JNMA; journal of the Nepal Medical Association. 2020 Oct 2:58(232):1011-1017. doi: 10.31729/jnma.5316.
73. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet (London, England). 2007 Aug 18:370(9587):591-603
74. Konstantinidis L,Guex-Crosier Y, Hypertension and the eye. Current opinion in ophthalmology. 2016
75. Kallistratos MS, Poulimenos LE, Manolis AJ. Atrial fibrillation and arterial hypertension. Pharmacological research. 2018 Feb:128():322-326. doi: 10.1016/j.phrs.2017.10.007.
76. Hegde, S., Ahmed, I., & Aeddula, N. (2023). Secondary hypertension. *StatPearls*